KMT2A and acute myeloid leukemia: BRDi was also found effective in treating non-MLL-rearranged AMLs such as those with NPM1 mutation (113) or deletion of chromosome 7 and 7q [−7/del(7q)] (114), supporting their broader application in AML therapeutics.